Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT06680206
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rimegepant — DRUG
    Rimegepant for acute treatment of migraine
  • Triptans — DRUG
    Triptans for acute treatment of migraine

Study Details

This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007). All data from the NHWS are reported by respondents, who are recruited through an existing, general-purpose, web-based, consumer panel via opt-in e-mails, co-registration with panel partners, e-newsletter campaigns, banner placements, and affiliate networks. All respondents explicitly agree to be a panel member, register with the panel through a unique e-mail address, and complete an in-depth demographic registration profile. This analysis will focus on respondents who self-report having migraine diagnosed by a physician. Individuals who use rimegepant for acute treatment of migraine will be compared with those who use triptans for acute treatment of migraine. Outcomes of interest include treatment satisfaction, healthcare resource utilization (HCRU), quality of life (QoL), work productivity loss, and migraine-specific disability outcomes. Inverse probability of treatment weighting (IPTW) will be used to adjust for differences that may exist between rimegepant and triptan users prior to comparing outcomes.

Key Dates

Start date
Oct 10, 2024
Status verified
Jan 2026
Primary completion
Nov 20, 2024
Completion
Nov 20, 2024

Study Design

Enrollment
1,395 participants (actual)

Arms

  • Arm: Acute treatment of migraine

Primary Outcome Measure

Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) [ Time Frame: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study. ]

Locations (1)

FacilityCityStateZIP
PfizerNew YorkNew York10001

Related coverage on Hipa.ai

Find similar trials in New York, NY

By condition
Migraine
By specialty
Neurology
By research site
Pfizer· New York, NY

Related Studies